PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide)

Rhea-AI Summary

PANTHERx Rare was chosen by Rhythm Pharmaceuticals (Nasdaq: RYTM) as the exclusive U.S. specialty pharmacy for the expanded indication of IMCIVREE (setmelanotide) for adults and children aged 4 and older with acquired hypothalamic obesity, announced March 20, 2026.

PANTHERx will deploy its RxARECARE model for individualized case management, education, and financial and insurance navigation. PANTHERx has served as IMCIVREE's exclusive pharmacy for certain genetic obesity indications since 2020.

Positive

• Exclusive U.S. distribution partner for IMCIVREE expanded indication
• Expanded patient cohort: adults and children 4+ with acquired hypothalamic obesity
• Established relationship: exclusive IMCIVREE pharmacy partner since 2020

Negative

• No financial terms disclosed for the exclusive distribution agreement

News Market Reaction – RYTM

-3.17%

3 alerts

-3.17% Session close to close

$6.17B Market Cap

1.09K Volume

In the Mar 20 session, RYTM declined 3.17%, reflecting a moderate negative market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details IMCIVREE’s expanded U.S. indication for acquired hypothalamic obesity and ...

Analysis

This announcement details IMCIVREE’s expanded U.S. indication for acquired hypothalamic obesity and confirms PANTHERx as the exclusive specialty pharmacy, alongside an 8-K describing pivotal TRANSCEND data with a placebo-adjusted -18.4% BMI reduction in 142 patients. Historically, Rhythm’s news flow mixed strong IMCIVREE revenue growth, a key PDUFA date, and mixed EMANATE outcomes. Investors may monitor prescription uptake in the estimated 10,000-patient U.S. population and potential use of the $200,000,000 ATM program.

Key Figures

TRANSCEND sample size: 142 patients BMI reduction primary: -18.4% BMI Setmelanotide arm BMI: -15.8% BMI +5 more

8 metrics

TRANSCEND sample size 142 patients Pivotal Phase 3 TRANSCEND trial in acquired hypothalamic obesity

BMI reduction primary -18.4% BMI Placebo-adjusted reduction in BMI in TRANSCEND trial

Setmelanotide arm BMI -15.8% BMI Change at 52 weeks in setmelanotide-treated patients (n=94)

Statistical significance p<0.0001 BMI difference vs placebo in TRANSCEND trial

U.S. HO population 10,000 people Estimated U.S. patients with acquired hypothalamic obesity

Registered resale shares 2,395,831 shares Common stock issuable upon conversion of Series A preferred

ATM capacity $200,000,000 At-the-market common stock offering agreement with TD Securities

Price move 5.18% Price change over prior 24 hours before this news context

Historical Context

5 past events · Latest: Mar 16 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 16	Phase 3 EMANATE data	Negative	-3.1%	Phase 3 EMANATE genetic obesity substudies failed to meet primary BMI endpoints.
Feb 26	Q4/FY25 earnings	Positive	-1.1%	Reported strong 2025 IMCIVREE revenue and cash with upcoming PDUFA and pipeline readouts.
Feb 17	Earnings date set	Neutral	+4.5%	Announced Q4/FY25 reporting date and conference participation details for early March 2026.
Feb 05	Conference participation	Neutral	-3.8%	CFO scheduled for Guggenheim Biotech Summit fireside chat with webcast access.
Jan 09	Prelim revenues/milestones	Positive	+3.6%	Prelim 2025 IMCIVREE revenue growth and setting PDUFA date and multiple 2026 clinical milestones.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news often produced single‑digit moves, with both positive and negative items sometimes met by counterintuitive reactions.

Recent Company History

Over the past few months, Rhythm has focused on expanding IMCIVREE and advancing its obesity pipeline. Preliminary and official 2025 results highlighted IMCIVREE net product revenue of about $194–195M and a PDUFA goal date of March 20, 2026 for acquired hypothalamic obesity. The EMANATE Phase 3 trial later missed predefined primary endpoints, while post hoc analyses showed pockets of BMI benefit. Against this backdrop, today’s news and 8‑K detail FDA approval for acquired hypothalamic obesity and a new distribution arrangement, building directly on the previously flagged PDUFA catalyst.

Key Terms

acquired hypothalamic obesity, hypothalamus, craniopharyngioma, astrocytoma, +4 more

8 terms

acquired hypothalamic obesity medical

"expanded indication of IMCIVREE ... for adults and children 4 years of age and older living with acquired hypothalamic obesity."

A condition in which damage to the brain’s hypothalamus—often from surgery, injury, or a tumor—disrupts the body’s internal “thermostat” for hunger, metabolism and energy use, causing rapid, hard-to-control weight gain. Investors care because it creates a clearly defined patient group with high unmet medical need, predictable clinical outcomes, and potential demand for therapies or devices; progress or setbacks in treating this condition can drive valuation swings for companies developing targeted treatments.

hypothalamus medical

"weight gain caused by an injury to the hypothalamus."

The hypothalamus is a small, deep brain structure that acts like the body's central thermostat and command center, controlling hunger, thirst, temperature, sleep, stress responses and the release of many hormones. For investors, it matters because therapies, drugs or devices that affect hypothalamus-driven systems can alter clinical outcomes, regulatory reviews and the market for treatments of obesity, sleep, endocrine and neurological conditions, so it is a common focus in medical development and trials.

craniopharyngioma medical

"most frequently follows the growth or treatment of craniopharyngioma, astrocytoma or other hypothalamic-pituitary tumors."

A craniopharyngioma is a benign (non-cancerous) tumor that grows near the base of the brain, often around the pituitary gland and vision pathways; imagine a small, misplaced lump pressing on critical plumbing and wiring in a house. It matters to investors because treatments, surgery risks, long-term hormone replacement needs, and potential recurrence can drive demand for specialized therapies, influence regulatory pathways, and affect the commercial value of drugs, devices, or diagnostics targeting this condition.

astrocytoma medical

"most frequently follows the growth or treatment of craniopharyngioma, astrocytoma or other hypothalamic-pituitary tumors."

A growth of abnormal cells in the brain that arises from astrocytes, the star-shaped cells that support neurons and maintain the brain’s environment. Investors watch astrocytoma because it drives demand for diagnostics, treatments, and clinical trials; news about successful drugs, trial results, or regulatory approvals can materially affect the finances of healthcare companies, similar to how a breakthrough fixes a major bottleneck in an industry.

hypothalamic-pituitary medical

"growth or treatment of craniopharyngioma, astrocytoma or other hypothalamic-pituitary tumors."

Hypothalamic-pituitary describes the connected control system between the hypothalamus (a small brain region) and the pituitary gland (a tiny hormone-producing organ beneath it) that regulates many body functions—think of it as the body's thermostat and command center for hormones. For investors, references to hypothalamic-pituitary function or dysfunction matter because therapies, diagnostics, or regulatory findings that affect this system can change clinical trial goals, safety profiles, market size, and the likelihood of regulatory approval.

traumatic brain injury medical

"Additional causes of injury may include traumatic brain injury, stroke or inflammation."

Traumatic brain injury (TBI) is damage to the brain caused by a sudden external force—like a blow, jolt, or penetration—that disrupts thinking, movement, senses, or emotion; think of the brain as a delicate computer that can short-circuit after a hard impact. For investors, TBI matters because it drives demand for medical devices, drugs, rehabilitation services, and long-term care, and it creates financial risks for insurers and companies facing liability or costly clinical research and regulatory hurdles.

bardet-biedl syndrome medical

"with obesity due to Bardet-Biedl Syndrome and proopiomelanocortin (POMC)..."

A rare inherited disorder caused by mutations in genes that act like a blueprint for the body, leading to a constellation of problems such as progressive vision loss, kidney dysfunction, obesity, extra fingers or toes, and developmental delays. Investors track it because treating or diagnosing the condition can create focused markets for drugs, genetic tests, medical devices, and long-term care services, and because clinical trial outcomes and regulatory decisions for therapies can materially affect company value.

proopiomelanocortin (pomc) medical

"Bardet-Biedl Syndrome and proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1..."

A precursor protein made in the brain and some other tissues that is cut into several active hormones controlling stress response, appetite, skin pigmentation and pain regulation; scientists call it POMC. Investors care because drugs or tests that change POMC production or the hormones it yields can become treatments or diagnostics for conditions like obesity, adrenal or pigmentation disorders, and pain—think of POMC as a single raw ingredient that can be turned into multiple valuable products.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PITTSBURGH, March 20, 2026 /PRNewswire/ -- PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, announced that it was selected by Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), as the exclusive U.S. Pharmacy distribution partner for the expanded indication of IMCIVREE® (setmelanotide) for adults and children 4 years of age and older living with acquired hypothalamic obesity.¹

Acquired hypothalamic obesity is a rare disease characterized by accelerated and sustained weight gain caused by an injury to the hypothalamus. Acquired hypothalamic obesity most frequently follows the growth or treatment of craniopharyngioma, astrocytoma or other hypothalamic-pituitary tumors. Additional causes of injury may include traumatic brain injury, stroke or inflammation.^{2, 3}

PANTHERx will leverage its proprietary and industry-leading RxARECARE® model to support patients, caregivers, and prescribers with therapy-specific clinical expertise. Through individualized case management, proactive education, and comprehensive financial and insurance navigation, PANTHERx makes complex rare disease therapies more personal, less overwhelming, and easier to access.

"This new indication for IMCIVREE marks an important scientific milestone for individuals and families affected by acquired hypothalamic obesity, a highly complex disease with historically limited therapeutic options," said Bansi Nagji, CEO of PANTHERx Rare. "We're honored to deepen our collaboration with Rhythm Pharmaceuticals, and to help patients receive the personalized, high-touch clinical support necessary to navigate treatment."

PANTHERx has been the exclusive pharmacy distribution partner for IMCIVREE for chronic weight management in adult and pediatric patients 2 years of age and older with obesity due to Bardet-Biedl Syndrome and proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing since 2020.¹

About PANTHERx Rare
PANTHERx Rare makes rare disease care more hyper-personalized and less overwhelming by focusing relentlessly on each patient and each therapy. PANTHERx experts develop deep personal relationships with patients, prescribers, and pharmaceutical partners, serving as trusted advocates to ensure seamless collaboration and exceptional care. Since its founding in a garage in Pittsburgh, PA in 2011, PANTHERx has grown into the largest independent rare pharmacy in the U.S., leveraging established-company resources while maintaining small-company responsiveness, innovation, and attention to detail.

PANTHERx is licensed in all 50 states and was the first national pharmacy to achieve dual accreditations in rare disease from the Accreditation Commission for Health Care (ACHC) and Utilization Review Accreditation Commission (URAC). PANTHERx is also the eight-time winner of the prestigious MMIT Patient Choice Award for patient satisfaction, including the 2025 honor.

About Acquired Hypothalamic Obesity
Acquired hypothalamic obesity is a rare disease characterized by accelerated and sustained weight gain caused by an injury to the hypothalamus. Hypothalamic injury may lead to decreased alpha-melanocyte-stimulating hormone (α-MSH) production and impairment of MC4R pathway signaling. The MC4R pathway is responsible for regulating energy balance and body weight. Acquired hypothalamic obesity most frequently follows the growth or treatment of craniopharyngioma, astrocytoma or other hypothalamic-pituitary tumors. Additional causes of injury may include traumatic brain injury, stroke or inflammation. Due to impairment of the MC4R pathway, patients experience accelerated and sustained weight gain, often accompanied by hyperphagia and/or decreased energy expenditure.

For more information, please email TheRareSP@pantherxrare.com or visit www.pantherxrare.com.

1. IMCIVREE (setmelanotide) Prescribing Information. https://rhythmtx.com/wp-content/uploads/2026/03/IMCIVREE-prescribing-information.pdf
2. Kim JH, Choi J-H. Pathophysiology and clinical characteristics of hypothalamic obesity in children and adolescents. Annals of Pediatric Endocrinology &amp; Metabolism. 2013;18(4):161. doi:10.6065/apem.2013.18.4.161
3. Acquired hypothalamic obesity. Rhythm Pharmaceuticals. Accessed March 3, 2026. Our Focus—Acquired Hypothalamic Obesity | Rhythm Pharmaceuticals

*RxARECARE® is a registered trademark of PANTHERx Specialty, LLC

PANTHERx Rare Media Contact:
Jennifer May, Senior Manager, Marketing Communications
jmay@pantherxrare.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/pantherx-rare-selected-by-rhythm-pharmaceuticals-inc-as-the-exclusive-us-specialty-pharmacy-for-the-expanded-indication-for-imcivree-setmelanotide-302720005.html

SOURCE PANTHERx Rare Pharmacy

FAQ

What did Rhythm Pharmaceuticals announce about IMCIVREE on March 20, 2026 (RYTM)?

Rhythm Pharmaceuticals named PANTHERx Rare the exclusive U.S. specialty pharmacy for IMCIVREE's expanded indication. According to Rhythm Pharmaceuticals, this covers adults and children 4+ with acquired hypothalamic obesity and aims to centralize patient support and distribution.

Who is eligible for IMCIVREE under the expanded indication announced by Rhythm (RYTM)?

Adults and children aged 4 years and older with acquired hypothalamic obesity are eligible under the expansion. According to Rhythm Pharmaceuticals, the indication targets patients with hypothalamic injury from tumors, injury, stroke, or inflammation.

What services will PANTHERx provide as the exclusive IMCIVREE pharmacy partner (RYTM)?

PANTHERx will provide individualized case management, proactive education, and insurance navigation. According to PANTHERx, their RxARECARE model delivers therapy-specific clinical support and financial assistance to patients and prescribers.

How does the IMCIVREE expanded indication affect pediatric patients (RYTM)?

The expansion allows pediatric treatment starting at age 4 for acquired hypothalamic obesity. According to Rhythm Pharmaceuticals, this broadens access for children previously without approved therapeutic options for this condition.

Has PANTHERx previously worked with IMCIVREE before the March 20, 2026 announcement (RYTM)?

Yes. PANTHERx has been the exclusive pharmacy distribution partner for IMCIVREE in certain genetic obesity indications since 2020. According to the companies, this extends an existing commercial relationship to the new indication.

Are the financial or commercial terms of the PANTHERx–Rhythm exclusive deal disclosed (RYTM)?

No financial or commercial terms were disclosed in the announcement. According to the companies, the release describes services and scope but does not provide pricing, revenue, or contract value details.